The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.
Nicholas J. Vogelzang
Consultant or Advisory Role - Algeta/Bayer
Svein Inge Helle
No relevant relationships to disclose
Dag Clement Johannessen
No relevant relationships to disclose
Joe M. O'Sullivan
No relevant relationships to disclose
Jose E. Garcia-Vargas
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BN ImmunoTherapeutics
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda